Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study

NCT02263326 is registered in ClinicalTrials.gov with Babafemi Taiwo as lead sponsor.

NCT NCT02263326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02263326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study
Lead sponsor
Babafemi Taiwo
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
September 30, 2017
Enrollment
89 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection